{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:29:36Z","timestamp":1787657376537,"version":"build-2736575974"},"reference-count":87,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T00:00:00Z","timestamp":1689465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Programa Inova Fiocruz","award":["VPPCB-008-FIO-18-2-49"],"award-info":[{"award-number":["VPPCB-008-FIO-18-2-49"]}]},{"name":"Programa Inova Fiocruz","award":["201.441\/2021"],"award-info":[{"award-number":["201.441\/2021"]}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["VPPCB-008-FIO-18-2-49"],"award-info":[{"award-number":["VPPCB-008-FIO-18-2-49"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["201.441\/2021"],"award-info":[{"award-number":["201.441\/2021"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Chromoblastomycosis (CBM) is a neglected human implantation mycosis caused by several dematiaceous fungal species. Currently available therapy is usually associated with physical methods, especially surgery, and with high refractoriness. Therefore, drug discovery for CBM is essential. Drug repositioning is a strategy used to facilitate the discovery of new treatments for several diseases. The aim of this study was to discover substances with antifungal activity against CBM agents from a collection of drugs previously approved for use in human diseases. A screening was performed with the NIH Clinical Collection against Fonsecaea pedrosoi. Ten substances, with clinical applicability in CBM, inhibited fungal growth by at least 60%. The minimum inhibitory concentration (MIC) of these substances was determined against other CBM agents, and the benzimidazoles albendazole, mebendazole and thiabendazole presented the lowest MIC values. The selectivity index, based on MIC and cytotoxicity of these substances, revealed albendazole to be more selective. To investigate a possible synergism of this benzimidazole with itraconazole and terbinafine, the chequerboard method was used. All interactions were classified as indifferent. Our current results suggest that benzimidazoles have repositioning potential against CBM agents. Albendazole seems to be the most promising, since it presented the highest selectivity against all dematiaceous fungi tested.<\/jats:p>","DOI":"10.3390\/jof9070753","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T01:06:36Z","timestamp":1689555996000},"page":"753","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Repurposing Benzimidazoles against Causative Agents of Chromoblastomycosis: Albendazole Has Superior In Vitro Activity Than Mebendazole and Thiabendazole"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4255-7486","authenticated-orcid":false,"given":"Rowena Alves","family":"Coelho","sequence":"first","affiliation":[{"name":"Laborat\u00f3rio de Micologia, Instituto Nacional de Infectologia Evandro Chagas, INI\/Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Helena Galdino","family":"Figueiredo-Carvalho","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Micologia, Instituto Nacional de Infectologia Evandro Chagas, INI\/Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7378-1990","authenticated-orcid":false,"given":"Fernando","family":"Almeida-Silva","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Micologia, Instituto Nacional de Infectologia Evandro Chagas, INI\/Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa Brito","family":"de Souza Rabello","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Micologia, Instituto Nacional de Infectologia Evandro Chagas, INI\/Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Rodrigues","family":"de Souza","sequence":"additional","affiliation":[{"name":"Plataforma de Bioensaios RPT 11B, Instituto Nacional de Infectologia Evandro Chagas, INI\/Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro Stefano","family":"Sangenito","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Estudos Avan\u00e7ados de Microrganismos Emergentes e Resistentes, Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Go\u00e9s, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil"},{"name":"Instituto Federal de Educa\u00e7\u00e3o, Ci\u00eancia e Tecnologia do Rio de Janeiro, Nil\u00f3polis 26530-060, RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna Sobrino","family":"Joffe","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Stony Brook University, Stony Brook, NY 11792, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0821-8592","authenticated-orcid":false,"given":"Andr\u00e9 Luis Souza dos","family":"Santos","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Estudos Avan\u00e7ados de Microrganismos Emergentes e Resistentes, Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Go\u00e9s, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil"},{"name":"Rede Micologia RJ, Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro (FAPERJ), Rio de Janeiro 21941-901, RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"da Silva Louren\u00e7o","sequence":"additional","affiliation":[{"name":"Plataforma de Bioensaios RPT 11B, Instituto Nacional de Infectologia Evandro Chagas, INI\/Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6081-3439","authenticated-orcid":false,"given":"Marcio L.","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Instituto Carlos Chagas, Funda\u00e7\u00e3o Oswaldo Cruz, Curitiba 81350-010, PR, Brazil"},{"name":"Instituto de Microbiologia, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6639-6058","authenticated-orcid":false,"given":"Rodrigo","family":"Almeida-Paes","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Micologia, Instituto Nacional de Infectologia Evandro Chagas, INI\/Fiocruz, Rio de Janeiro 21040-900, RJ, Brazil"},{"name":"Rede Micologia RJ, Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro (FAPERJ), Rio de Janeiro 21941-901, RJ, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/13693786.2010.539631","article-title":"Mycoses of Implantation in Latin America: An Overview of Epidemiology, Clinical Manifestations, Diagnosis and Treatment","volume":"49","author":"Nucci","year":"2011","journal-title":"Med. Mycol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1128\/CMR.00032-16","article-title":"Chromoblastomycosis","volume":"30","author":"Santos","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1128\/EC.00314-12","article-title":"A Repurposing Approach Identifies Off-Patent Drugs with Fungicidal Cryptococcal Activity, a Common Structural Chemotype, and Pharmacological Properties Relevant to the Treatment of Cryptococcosis","volume":"12","author":"Butts","year":"2013","journal-title":"Eukaryot. Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug Repurposing: Progress, Challenges and Recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.mib.2003.08.003","article-title":"Why Is Big Pharma Getting out of Antibacterial Drug Discovery?","volume":"6","author":"Projan","year":"2003","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1128\/microbiolspec.FUNK-0002-2016","article-title":"Antifungal Drugs: The Current Armamentarium and Development of New Agents","volume":"4","author":"Robbins","year":"2016","journal-title":"Microbiol. Spectr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrd.2017.46","article-title":"The Antifungal Pipeline: A Reality Check","volume":"16","author":"Perfect","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/annonc\/mdx053","article-title":"Clinical Benefit, Price and Approval Characteristics of FDA-Approved New Drugs for Treating Advanced Solid Cancer, 2000\u20132015","volume":"28","author":"Vivot","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1039\/C3NP70070D","article-title":"Discovery and Development of First in Class Antifungal Caspofungin (CANCIDAS\u00ae)\u2014A Case Study","volume":"31","author":"Balkovec","year":"2014","journal-title":"Nat. Prod. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1086\/504492","article-title":"Pharmacology of Systemic Antifungal Agents","volume":"43","author":"Ashley","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s40265-014-0276-7","article-title":"Tavaborole: First Global Approval","volume":"74","author":"Markham","year":"2014","journal-title":"Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s40265-013-0152-x","article-title":"Efinaconazole: First Global Approval","volume":"73","author":"Patel","year":"2013","journal-title":"Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40265-015-0398-6","article-title":"Isavuconazonium: First Global Approval","volume":"75","author":"McCormack","year":"2015","journal-title":"Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s40265-021-01571-5","article-title":"Ibrexafungerp: First Approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40265-022-01734-y","article-title":"Oteseconazole: First Approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1128\/AAC.01655-09","article-title":"In Vitro Activities of Eight Antifungal Drugs against 55 Clinical Isolates of Fonsecaea Spp","volume":"54","author":"Najafzadeh","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11046-013-9634-3","article-title":"Chromoblastomycosis Due to Fonsecaea pedrosoi and F. monophora in Cuba","volume":"175","author":"Badali","year":"2013","journal-title":"Mycopathologia"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Coelho, R.A., Brito-Santos, F., Figueiredo-Carvalho, M.H.G., Silva, J.V.D.S., Gutierrez-Galhardo, M.C., do Valle, A.C.F., Zancop\u00e9-Oliveira, R.M., Trilles, L., Meyer, W., and Freitas, D.F.S. (2018). Molecular Identification and Antifungal Susceptibility Profiles of Clinical Strains of Fonsecaea Spp. Isolated from Patients with Chromoblastomycosis in Rio de Janeiro, Brazil. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006675"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3390\/microbiolres13020017","article-title":"Does DHN-Melanin Always Protect Fungi against Antifungal Drugs? The Fonsecaea\/Micafungin Paradigm","volume":"13","author":"Coelho","year":"2022","journal-title":"Microbiol. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/cmdc.201700259","article-title":"Repurposing of Human Kinase Inhibitors in Neglected Protozoan Diseases","volume":"12","author":"Dichiara","year":"2017","journal-title":"ChemMedChem"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1017\/S0031182017000993","article-title":"Repurposing as a Strategy for the Discovery of New Anti-Leishmanials: The-State-of-the-Art","volume":"145","author":"Charlton","year":"2018","journal-title":"Parasitology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fmicb.2019.00041","article-title":"Drug Repurposing for the Treatment of Bacterial and Fungal Infections","volume":"10","author":"Smani","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.drudis.2011.02.016","article-title":"In Silico Repositioning of Approved Drugs for Rare and Neglected Diseases","volume":"16","author":"Ekins","year":"2011","journal-title":"Drug Discov. Today"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mib.2020.03.005","article-title":"Antifungal Drug Screening: Thinking Outside the Box to Identify Novel Antifungal Scaffolds","volume":"57","author":"Beattie","year":"2020","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/2589977513666210211163711","article-title":"Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery","volume":"13","author":"Roy","year":"2021","journal-title":"Curr. Drug Res. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1128\/AAC.00212-12","article-title":"The Antidepressant Sertraline Provides a Promising Therapeutic Option for Neurotropic Cryptococcal Infections","volume":"56","author":"Zhai","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S1473-3099(16)00074-8","article-title":"Efficacy of Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis: An Open-Label Dose-Ranging Study","volume":"16","author":"Rhein","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1007\/s00253-021-11407-7","article-title":"Drug Repurposing Strategies in the Development of Potential Antifungal Agents","volume":"105","author":"Zhang","year":"2021","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e02063-19","DOI":"10.1128\/AAC.02063-19","article-title":"In Vitro Antifungal Susceptibility of the Emerging Multidrug-Resistant Pathogen Candida Auris to Miltefosine Alone and in Combination with Amphotericin B","volume":"64","author":"Wu","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ps.5520","article-title":"Stereoselective Bioactivity, Toxicity and Degradation of the Chiral Triazole Fungicide Bitertanol","volume":"76","author":"Li","year":"2019","journal-title":"Pest Manag. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"116827","DOI":"10.1016\/j.lfs.2019.116827","article-title":"In Vitro Synergy of Azole Antifungals and Methotrexate against Candida albicans","volume":"235","author":"Yang","year":"2019","journal-title":"Life Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1089\/adt.2015.29007.ghkdrrr","article-title":"Antiepileptic Drugs Inhibit Growth, Dimorphism, and Biofilm Mode of Growth in Human Pathogen Candida albicans","volume":"13","author":"Kathwate","year":"2015","journal-title":"ASSAY Drug Dev. Technol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Santos, D.W.C.L., de Azevedo, C.d.M.P.E.S., Vicente, V.A., Queiroz-Telles, F., Rodrigues, A.M., de Hoog, G.S., Denning, D.W., and Colombo, A.L. (2021). The Global Burden of Chromoblastomycosis. PLoS Negl. Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0009611"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3389\/fmicb.2017.00535","article-title":"The Anti-Helminthic Compound Mebendazole Has Multiple Antifungal Effects against Cryptococcus neoformans","volume":"8","author":"Joffe","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_36","first-page":"571.e1-4","article-title":"EUCAST DEFINITIVE DOCUMENT E.DEF 9.3.1\u2014Method for the Determination of Broth Dilution Minimum Inhibitory Concentrations of Antifungal Agents for Conidia Forming Moulds","volume":"22","author":"Arendrup","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_37","unstructured":"CLSI\u2014Clinical and Laboratory Standars Institute (2008). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi, Clinical and Laboratory Standards Institute. CLSI Document M38-A2; Approved Standard-Second Edition."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2174\/1874285801105010096","article-title":"Inhibition of Growth of Highly Resistant Bacterial and Fungal Pathogens by a Natural Product","volume":"5","author":"Hafidh","year":"2011","journal-title":"Open Microbiol. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1128\/AAC.46.8.2708-2711.2002","article-title":"In Vitro Susceptibilities of Zygomycetes to Combinations of Antimicrobial Agents","volume":"46","author":"Dannaoui","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1128\/AAC.41.8.1812","article-title":"In Vitro Activities of Terbinafine in Combination with Fluconazole and Itraconazole against Isolates of Candida albicans with Reduced Susceptibility to Azoles","volume":"41","author":"Barchiesi","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0732-8893(02)00509-6","article-title":"In Vitro Evaluation of Combination of Terbinafine with Itraconazole or Amphotericin B against Zygomycota","volume":"45","author":"Mellado","year":"2003","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/978-1-60761-756-3_21","article-title":"A Cellular Viability Assay to Monitor Drug Toxicity","volume":"648","author":"Hansen","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"ref_43","unstructured":"Markossian, S., Grossman, A., Brimacombe, K., Arkin, M., Auld, D., Austin, C., Baell, J., Chung, T.D.Y., Coussens, N.P., and Dahlin, J.L. (2004). Assay Guidance Manual, Eli Lilly & Company and the National Center for Advancing Translational Sciences."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1128\/jb.52.4.461-466.1946","article-title":"Urea Decomposition as a Means of Differentiating Proteus and Paracolon Cultures from Each Other and from Salmonella and Shigella Types","volume":"52","author":"Christensen","year":"1946","journal-title":"J. Bacteriol."},{"key":"ref_46","first-page":"212308","article-title":"Phenotypic Characteristics Associated with Virulence of Clinical Isolates from the Sporothrix Complex","volume":"2015","author":"Oliveira","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"de Andrade, I.B., Corr\u00eaa-Junior, D., Alves, V., Figueiredo-Carvalho, M.H.G., Santos, M.V., Almeida, M.A., Valdez, A.F., Nimrichter, L., Almeida-Paes, R., and Frases, S. (2023). Cyclosporine Affects the Main Virulence Factors of Cryptococcus neoformans In Vitro. J. Fungi, 9.","DOI":"10.3390\/jof9040487"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"foy119","DOI":"10.1093\/femsyr\/foy119","article-title":"Pharmacological Inhibition of Pigmentation in Cryptococcus","volume":"19","author":"Zimbres","year":"2019","journal-title":"FEMS Yeast Res."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Almeida, M.A., Bernardes-Engemann, A.R., Coelho, R.A., Lugones, C.J.G., de Andrade, I.B., Corr\u00eaa-Junior, D., de Oliveira, S.S.C., Dos Santos, A.L.S., Frases, S., and Rodrigues, M.L. (2023). Mebendazole Inhibits Histoplasma Capsulatum In Vitro Growth and Decreases Mitochondrion and Cytoskeleton Protein Levels. J. Fungi, 9.","DOI":"10.3390\/jof9030385"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1590\/abd1806-4841.20187321","article-title":"de J.S. Chromoblastomycosis: An Etiological, Epidemiological, Clinical, Diagnostic, and Treatment Update","volume":"93","author":"Bittencourt","year":"2018","journal-title":"An. Bras. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11046-006-0041-x","article-title":"Cellular Immune Response of Patients with Chromoblastomycosis Undergoing Antifungal Therapy","volume":"162","author":"Gimenes","year":"2006","journal-title":"Mycopathologia"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Silva, A.A.d.L., Criado, P.R., Nunes, R.S., da Silva, W.L.F., Kanashiro-Galo, L., Duarte, M.I.S., Sotto, M.N., and Pagliari, C. (2014). In Situ Immune Response in Human Chromoblastomycosis\u2014A Possible Role for Regulatory and Th17 T Cells. PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0003162"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/ijd.14185","article-title":"Chromoblastomycosis: Clinical Experience and Review of Literature","volume":"57","year":"2018","journal-title":"Int. J. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1517\/14656566.5.2.247","article-title":"Treating Chromoblastomycosis with Systemic Antifungals","volume":"5","author":"Bonifaz","year":"2004","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1439-0507.2004.00984.x","article-title":"Susceptibility of Sequential Fonsecaea pedrosoi Isolates from Chromoblastomycosis Patients to Antifungal Agents","volume":"47","author":"Andrade","year":"2004","journal-title":"Mycoses"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13693780802538001","article-title":"Chromoblastomycosis: An Overview of Clinical Manifestations, Diagnosis and Treatment","volume":"47","author":"Esterre","year":"2009","journal-title":"Med. Mycol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0190-9622(83)70001-0","article-title":"Chromoblastomycosis and Phaeohyphomycosis: New Concepts, Diagnosis, and Mycology","volume":"8","author":"McGinnis","year":"1983","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo. The Cardiac Arrhythmia Suppression Trial","volume":"324","author":"Echt","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_59","first-page":"126","article-title":"Oxiconazole Nitrate: Pharmacology, Efficacy, and Safety of a New Imidazole Antifungal Agent","volume":"13","author":"Jegasothy","year":"1991","journal-title":"Clin. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s15010-017-1059-3","article-title":"Clinical Evaluation of the Antifungal Effect of Sertraline in the Treatment of Cryptococcal Meningitis in HIV Patients: A Single Mexican Center Experience","volume":"46","year":"2018","journal-title":"Infection"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/jac\/dky455","article-title":"In Vivo Evaluation of the Antifungal Activity of Sertraline against Aspergillus fumigatus","volume":"74","author":"Montoya","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/jam.14490","article-title":"Sertraline as a Promising Antifungal Agent: Inhibition of Growth and Biofilm of Candida Auris with Special Focus on the Mechanism of Action in Vitro","volume":"128","author":"Gowri","year":"2020","journal-title":"J. Appl. Microbiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.1016\/j.bmc.2012.09.013","article-title":"The Therapeutic Journey of Benzimidazoles: A Review","volume":"20","author":"Bansal","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.2174\/1568026616666160506130226","article-title":"Antimicrobial Activities of 1-H-Benzimidazole-Based Molecules","volume":"16","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e01909-17","DOI":"10.1128\/AAC.01909-17","article-title":"Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease","volume":"62","author":"Nixon","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1021\/acsinfecdis.1c00063","article-title":"Docusate-Based Ionic Liquids of Anthelmintic Benzimidazoles Show Improved Pharmaceutical Processability, Lipid Solubility, and in Vitro Activity against Cryptococcus neoformans","volume":"7","author":"Sutar","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e00286-20","DOI":"10.1128\/AAC.00286-20","article-title":"Fenbendazole Controls In Vitro Growth, Virulence Potential, and Animal Infection in the Cryptococcus Model","volume":"64","author":"Joffe","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/jac\/dkg245","article-title":"In Vitro Susceptibility of Aspergillus Spp. Clinical Isolates to Albendazole","volume":"51","author":"Berthet","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1128\/AAC.38.2.378","article-title":"In Vitro Susceptibility of the Opportunistic Fungus Cryptococcus neoformans to Anthelmintic Benzimidazoles","volume":"38","author":"Cruz","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00443822","article-title":"Histopathology of Chromoblastomycosis","volume":"105","author":"Uribe","year":"1989","journal-title":"Mycopathologia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1001\/archderm.1971.04000230018003","article-title":"Chromomycosis. Treatment with Thiabendazole","volume":"104","author":"Bayles","year":"1971","journal-title":"Arch. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/0035-9203(83)90287-0","article-title":"A Case of Chromomycosis Treated with Thiabendazole","volume":"77","author":"Domingo","year":"1983","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_73","first-page":"413","article-title":"[Chromomycosis. Treatment with a combination of thiabendazole and 5-fluorocytosine, 6-year follow-up]","volume":"11","author":"Solano","year":"1983","journal-title":"Med. Cutan. Ibero. Lat. Am."},{"key":"ref_74","first-page":"307","article-title":"[Treatment effectiveness of chromomycoses by surgery-thiabendazole in Madagascar (Fort Dauphin)]","volume":"59","author":"Michel","year":"1999","journal-title":"Med. Trop."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2133.1996.tb15658.x","article-title":"Treatment of Chromomycosis with Terbinafine: Preliminary Results of an Open Pilot Study","volume":"134","author":"Esterre","year":"1996","journal-title":"Br. J. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0001-706X(03)00031-7","article-title":"Albendazole, Mebendazole and Praziquantel. Review of Non-Clinical Toxicity and Pharmacokinetics","volume":"86","author":"Dayan","year":"2003","journal-title":"Acta Trop."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Marslin, G., Siram, K., Liu, X., Khandelwal, V.K.M., Xiaolei, S., Xiang, W., and Franklin, G. (2017). Solid Lipid Nanoparticles of Albendazole for Enhancing Cellular Uptake and Cytotoxicity against U-87 MG Glioma Cell Lines. Molecules, 22.","DOI":"10.3390\/molecules22112040"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"105552","DOI":"10.1016\/j.ejps.2020.105552","article-title":"A Combined in Vitro In silico Approach to Predict the Oral Bioavailability of Borderline BCS Class II\/IV Weak Base Albendazole and Its Main Metabolite Albendazole Sulfoxide","volume":"155","author":"Pettarin","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00001432-200304000-00005","article-title":"Melanin and Fungi","volume":"16","author":"Nosanchuk","year":"2003","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/jobm.202000664","article-title":"Melanin and Chromoblastomycosis Agents: Characterization, Functions, and Relation with Antifungals","volume":"61","author":"Koehler","year":"2021","journal-title":"J. Basic Microbiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/IAI.72.1.229-237.2004","article-title":"Melanin from Fonsecaea pedrosoi Induces Production of Human Antifungal Antibodies and Enhances the Antimicrobial Efficacy of Phagocytes","volume":"72","author":"Alviano","year":"2004","journal-title":"Infect. Immun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1590\/S0036-46652008000500004","article-title":"Secretion of Five Extracellular Enzymes by Strains of Chromoblastomycosis Agents","volume":"50","author":"Scroferneker","year":"2008","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"104367","DOI":"10.1016\/j.micpath.2020.104367","article-title":"A Comparative Study of Extracellular Enzymes from Chromoblastomycosis Agents Reveals the Potential Association of Phospholipase with the Severity of the Lesions","volume":"147","author":"Montoya","year":"2020","journal-title":"Microb. Pathog."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4236\/ojmm.2014.41006","article-title":"Overview on the Fungal Metabolites Involved in Mycopathy","volume":"4","year":"2014","journal-title":"Open J. Med. Microbiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1128\/AAC.02190-15","article-title":"Activation of Melanin Synthesis in Alternaria Infectoria by Antifungal Drugs","volume":"60","author":"Fernandes","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.micpath.2018.07.028","article-title":"A Potential of Propolis on Major Virulence Factors of Cryptococcus neoformans","volume":"123","author":"Thammasit","year":"2018","journal-title":"Microb. Pathog."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2478\/sjdv-2020-0002","article-title":"Office-made 4% Albendazole Cream is an Effective Alternative Therapy for Cutaneous Larva Migrans: A Report of Three Cases","volume":"12","author":"Mulia","year":"2020","journal-title":"Serbian J. Dermatol. Venereol."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/9\/7\/753\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:13:02Z","timestamp":1760127182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/9\/7\/753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,16]]},"references-count":87,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["jof9070753"],"URL":"https:\/\/doi.org\/10.3390\/jof9070753","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,16]]}}}